BioMedNewsBreaks

WednesdayJul 17, 2024 10:25 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Enters Strategic Partnership to Support Rollout of Telemedicine Services across the US

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, is announcing a strategic partnership with HC Smart, Inc., a national telemedicine provider. The partnership, set to go live within the next four weeks, is expected to extend HealthLynked’s telemedicine services across the U.S. as well as significantly enhance the company’s offerings and accessibility. The announcement stated that the collaboration will integrate HC Smart’s advanced telemedicine capabilities into HealthLynked’s existing platform, providing nationwide coverage to all HealthLynked members. This initiative will offer HealthLynked Network members access to high-quality healthcare from the comfort of their homes by enabling reduced-cost telemedicine consultations as part…

Continue Reading

TuesdayJul 16, 2024 3:38 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert served as chief of the neurooncology branch at NIH for a decade. During that time, Gilbert facilitated a team of laboratory and clinical investigators involved in groundbreaking research that advanced science in the brain tumor field. In addition to his experience at NIH, Gilbert practiced under world-renowned…

Continue Reading

TuesdayJul 16, 2024 3:00 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Closes $8.75M Underwritten Public Offering

Bluejay (NASDAQ: BJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock or one pre-funded warrant to purchase one share of common Stock, two Class C warrants each to purchase one share of common stock and one Class D warrant to purchase such number of shares of…

Continue Reading

TuesdayJul 16, 2024 2:41 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Exec to Present at Upcoming Virtual Investor Closing Bell Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be presenting via a live video webcast at 4 p.m. on July 17. The presentation will include a corporate overview and will also feature a live question-and-answer period. A replay of the webcast will be available following the live presentation and will be accessible for 90 days. To view the presentation, visit https://ibn.fm/Uy7c6 To…

Continue Reading

TuesdayJul 16, 2024 1:05 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form,” the announcement reads. “The company conducted comprehensive bridge studies in various solvents and in animals, comparing the old…

Continue Reading

MondayJul 15, 2024 11:15 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes. Nutriband's proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is…

Continue Reading

MondayJul 15, 2024 10:40 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), which is being studied as a local, first-of-its-kind, intralesional biological treatment for from mild to moderate plaque psoriasis. An estimated million patients are diagnosed with plaque psoriasis in the United States, Japan and Europe. Scinai's product candidate is designed to address the major shortcomings of…

Continue Reading

FridayJul 12, 2024 2:32 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Management Slated to Participate in Upcoming Emerging Growth Conference

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will be participating in next week’s Emerging Growth Conference. According to the announcement, members of Clene’s management team will be presenting at the one-day conference, which is scheduled for July 18, 2024. The online presentation, which will begin at 4:45 p.m. EDT, will include a corporate update as well as a question-and-answer session. A webcast of the presentation will be available on the…

Continue Reading

FridayJul 12, 2024 2:11 pm

BioMedNewsBreaks — Astiva Health Providing Tailored Approach to Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, recognizes that successful treatment outcomes are largely dependent on the patient, with 90% of treatment success attributed to patient involvement. Patient engagement can lead to reduced hospitalizations as well as improve effectiveness, efficiency, quality of health services, quality of life, and responsiveness. “Astiva Health is leading the way in offering a Medicare Advantage Prescription Drug (‘MAPD’) health plan committed to reshaping the landscape of personalized and comprehensive healthcare by involving patients more completely in their own treatment,” a recent article reads. “The…

Continue Reading

ThursdayJul 11, 2024 2:00 pm

BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment

InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Degeneration (“AMD”) and its INM-901 small molecule drug candidate targeting Alzheimer’s disease (“AD”). “Recent preclinical data for INM-089 demonstrated significant functional and pathological improvements in an AMD disease model, indicating promising neuroprotective effects in the back of the eye… INM-901 is currently being investigated for its potential in treating Alzheimer’s disease. Recent preclinical data showcased its positive pharmacological effects, demonstrating reduced…

Continue Reading